Related Searches: Tea Vitamin Nutrients Ingredients paper cup packing

Food & Health Ingredients
Health & Nutrition
Processing & Packaging
Starch & Starch Derivatives
You are here: Home >news >Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices

Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices

Share       

FDAs unique device identification system is designed to adequately identify devices through distribution and use. Its requirements were designed to be phased in over seven years according to established compliance dates based primarily on device classification.

The compliance dates established for class I and unclassified devices, other than implantable, life-supporting, or life-sustaining (I/LS/LS) devices are:

  • September 24, 2018, for the following requirements:
    • Standard date formatting (21 CFR 801.18),
    • Labeling (21 CFR 801.20, 21 CFR 801.50), and
    • Global Unique Device Identification Database (GUDID) data submission (21 CFR 830.300); and
  • September 24, 2020, for direct mark requirements (21 CFR 801.45).

This guidance describes FDAs intention with regard to enforcement of these requirements for class I and unclassified devices.

This guidance also describes FDAs direct mark compliance policy for class III, LS/LS, and class II devices that are non-sterile, that are manufactured and labeled prior to their applicable direct mark compliance date, and that remain in inventory, as well as for class I and unclassified devices that are not LS/LS devices, that are non-sterile, that are manufactured and labeled prior to September 24, 2022, and that remain in inventory.

Throughout this guidance document, the terms "we," "us," and "our" refer to FDA staff from the Center for Devices and Radiological Health (CDRH) and the Center for Biologics evaluation and Research (CBER). "You" and "your" refer to the labeler, as defined in 21 CFR 801.3.

This guidance is being implemented without prior public comment because the Agency has determined that prior public participation is not feasible or appropriate (section 701(h)(1)(C)(i) of the FD&C Act and 21 CFR 10.115(g)(2)). FDA has determined that this guidance document presents a less burdensome policy that is consistent with public health. This guidance document is being implemented immediately, but it remains subject to comment in accordance with the Agencys good guidance practices.

E-newsletter

Subscribe to our e-newsletter for the latest food ingredients news and trends.

Tags

SJGLE B2B Website : 中文版 | ChineseCustomer Service: 86-400 610 1188-3 ( Mon-Fri 9: 00-18: 00 BJT)

About Us|Contact Us|Privacy Policy|Intellectual Property Statement

Copyright 2006-2023 Shanghai Sinoexpo Informa Markets International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-121  沪公网安备31010402001403号

Inquiry Basket

Inquiry Basket

Buyer service

Buyer service

Supplier service

Supplier service

Top

Top